Cargando…
Prevalence, Risk Factors, and Treatment Outcomes of Isoniazid- and Rifampicin- Mono-Resistant Pulmonary Tuberculosis in Lima, Peru
BACKGROUND: Isoniazid and rifampicin are the two most efficacious first-line agents for tuberculosis (TB) treatment. We assessed the prevalence of isoniazid and rifampicin mono-resistance, associated risk factors, and the association of mono-resistance on treatment outcomes. METHODS: A prospective,...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821555/ https://www.ncbi.nlm.nih.gov/pubmed/27045684 http://dx.doi.org/10.1371/journal.pone.0152933 |
_version_ | 1782425608618246144 |
---|---|
author | Villegas, Leonela Otero, Larissa Sterling, Timothy R. Huaman, Moises A. Van der Stuyft, Patrick Gotuzzo, Eduardo Seas, Carlos |
author_facet | Villegas, Leonela Otero, Larissa Sterling, Timothy R. Huaman, Moises A. Van der Stuyft, Patrick Gotuzzo, Eduardo Seas, Carlos |
author_sort | Villegas, Leonela |
collection | PubMed |
description | BACKGROUND: Isoniazid and rifampicin are the two most efficacious first-line agents for tuberculosis (TB) treatment. We assessed the prevalence of isoniazid and rifampicin mono-resistance, associated risk factors, and the association of mono-resistance on treatment outcomes. METHODS: A prospective, observational cohort study enrolled adults with a first episode of smear-positive pulmonary TB from 34 health facilities in a northern district of Lima, Peru, from March 2010 through December 2011. Participants were interviewed and a sputum sample was cultured on Löwenstein-Jensen (LJ) media. Drug susceptibility testing was performed using the proportion method. Medication regimens were documented for each patient. Our primary outcomes were treatment outcome at the end of treatment. The secondary outcome included recurrent episodes among cured patients within two years after completion of the treatment. RESULTS: Of 1292 patients enrolled, 1039 (80%) were culture-positive. From this subpopulation, isoniazid mono-resistance was present in 85 (8%) patients and rifampicin mono-resistance was present in 24 (2%) patients. In the multivariate logistic regression model, isoniazid mono-resistance was associated with illicit drug use (adjusted odds ratio (aOR) = 2.10; 95% confidence interval (CI): 1.1–4.1), and rifampicin mono-resistance was associated with HIV infection (aOR = 9.43; 95%CI: 1.9–47.8). Isoniazid mono-resistant patients had a higher risk of poor treatment outcomes including treatment failure (2/85, 2%, p-value<0.01) and death (4/85, 5%, p<0.02). Rifampicin mono-resistant patients had a higher risk of death (2/24, 8%, p<0.01). CONCLUSION: A high prevalence of isoniazid and rifampicin mono-resistance was found among TB patients in our low HIV burden setting which were similar to regions with high HIV burden. Patients with isoniazid and rifampicin mono-resistance had an increased risk of poor treatment outcomes. |
format | Online Article Text |
id | pubmed-4821555 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-48215552016-04-22 Prevalence, Risk Factors, and Treatment Outcomes of Isoniazid- and Rifampicin- Mono-Resistant Pulmonary Tuberculosis in Lima, Peru Villegas, Leonela Otero, Larissa Sterling, Timothy R. Huaman, Moises A. Van der Stuyft, Patrick Gotuzzo, Eduardo Seas, Carlos PLoS One Research Article BACKGROUND: Isoniazid and rifampicin are the two most efficacious first-line agents for tuberculosis (TB) treatment. We assessed the prevalence of isoniazid and rifampicin mono-resistance, associated risk factors, and the association of mono-resistance on treatment outcomes. METHODS: A prospective, observational cohort study enrolled adults with a first episode of smear-positive pulmonary TB from 34 health facilities in a northern district of Lima, Peru, from March 2010 through December 2011. Participants were interviewed and a sputum sample was cultured on Löwenstein-Jensen (LJ) media. Drug susceptibility testing was performed using the proportion method. Medication regimens were documented for each patient. Our primary outcomes were treatment outcome at the end of treatment. The secondary outcome included recurrent episodes among cured patients within two years after completion of the treatment. RESULTS: Of 1292 patients enrolled, 1039 (80%) were culture-positive. From this subpopulation, isoniazid mono-resistance was present in 85 (8%) patients and rifampicin mono-resistance was present in 24 (2%) patients. In the multivariate logistic regression model, isoniazid mono-resistance was associated with illicit drug use (adjusted odds ratio (aOR) = 2.10; 95% confidence interval (CI): 1.1–4.1), and rifampicin mono-resistance was associated with HIV infection (aOR = 9.43; 95%CI: 1.9–47.8). Isoniazid mono-resistant patients had a higher risk of poor treatment outcomes including treatment failure (2/85, 2%, p-value<0.01) and death (4/85, 5%, p<0.02). Rifampicin mono-resistant patients had a higher risk of death (2/24, 8%, p<0.01). CONCLUSION: A high prevalence of isoniazid and rifampicin mono-resistance was found among TB patients in our low HIV burden setting which were similar to regions with high HIV burden. Patients with isoniazid and rifampicin mono-resistance had an increased risk of poor treatment outcomes. Public Library of Science 2016-04-05 /pmc/articles/PMC4821555/ /pubmed/27045684 http://dx.doi.org/10.1371/journal.pone.0152933 Text en © 2016 Villegas et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Villegas, Leonela Otero, Larissa Sterling, Timothy R. Huaman, Moises A. Van der Stuyft, Patrick Gotuzzo, Eduardo Seas, Carlos Prevalence, Risk Factors, and Treatment Outcomes of Isoniazid- and Rifampicin- Mono-Resistant Pulmonary Tuberculosis in Lima, Peru |
title | Prevalence, Risk Factors, and Treatment Outcomes of Isoniazid- and Rifampicin- Mono-Resistant Pulmonary Tuberculosis in Lima, Peru |
title_full | Prevalence, Risk Factors, and Treatment Outcomes of Isoniazid- and Rifampicin- Mono-Resistant Pulmonary Tuberculosis in Lima, Peru |
title_fullStr | Prevalence, Risk Factors, and Treatment Outcomes of Isoniazid- and Rifampicin- Mono-Resistant Pulmonary Tuberculosis in Lima, Peru |
title_full_unstemmed | Prevalence, Risk Factors, and Treatment Outcomes of Isoniazid- and Rifampicin- Mono-Resistant Pulmonary Tuberculosis in Lima, Peru |
title_short | Prevalence, Risk Factors, and Treatment Outcomes of Isoniazid- and Rifampicin- Mono-Resistant Pulmonary Tuberculosis in Lima, Peru |
title_sort | prevalence, risk factors, and treatment outcomes of isoniazid- and rifampicin- mono-resistant pulmonary tuberculosis in lima, peru |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821555/ https://www.ncbi.nlm.nih.gov/pubmed/27045684 http://dx.doi.org/10.1371/journal.pone.0152933 |
work_keys_str_mv | AT villegasleonela prevalenceriskfactorsandtreatmentoutcomesofisoniazidandrifampicinmonoresistantpulmonarytuberculosisinlimaperu AT oterolarissa prevalenceriskfactorsandtreatmentoutcomesofisoniazidandrifampicinmonoresistantpulmonarytuberculosisinlimaperu AT sterlingtimothyr prevalenceriskfactorsandtreatmentoutcomesofisoniazidandrifampicinmonoresistantpulmonarytuberculosisinlimaperu AT huamanmoisesa prevalenceriskfactorsandtreatmentoutcomesofisoniazidandrifampicinmonoresistantpulmonarytuberculosisinlimaperu AT vanderstuyftpatrick prevalenceriskfactorsandtreatmentoutcomesofisoniazidandrifampicinmonoresistantpulmonarytuberculosisinlimaperu AT gotuzzoeduardo prevalenceriskfactorsandtreatmentoutcomesofisoniazidandrifampicinmonoresistantpulmonarytuberculosisinlimaperu AT seascarlos prevalenceriskfactorsandtreatmentoutcomesofisoniazidandrifampicinmonoresistantpulmonarytuberculosisinlimaperu |